Articles tagged with "Gout"

Tigulixostat Appears Promising for the Treatment of Gout

Michele B. Kaufman, PharmD, BCGP | February 2, 2022

In a phase 2 study, tigulixostat treatment proved safe for lowering serum uric acid (sUA) levels in patients with gout.

Study: Pegloticase & Methotrexate Co-Treatment Helps Uncontrolled Gout

Vanessa Caceres | January 10, 2022

A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (methotrexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of Rheumatology.1 The MIRROR study…

Pegloticase Proves Promising for Gout in Patients Who Have Undergone Kidney Transplant

Michele B. Kaufman, PharmD, BCGP | December 8, 2021

Patients who have undergone a kidney transplant and have high levels of serum uric acid symptomatic gout may benefit from treatment with pegloticase, according to a recent study.

10 Clinical Insights & Rheumatology Pearls Presented at ACR Convergence 2021

Mithu Maheswaranathan, MD | December 2, 2021

Practical tips for the diagnosis, evaluation and treatment of a spectrum of conditions commonly encountered in a rheumatology practice are offered.

Gout, Imaging & Cardiovascular Disease: 2 Experts Discuss Challenging Patients & Advanced Imaging

Samantha C. Shapiro, MD | November 23, 2021

Experts compare using ultrasound and dual-energy computed tomography (DECT) scan when diagnosing likely gout patients, and discuss the latest insights into the intersection between gout and cardiovascular disease.

Updates on ACR Gout Guideline, FDA’s Febuxostat Warning & Pegloticase Therapy

Jason Liebowitz, MD, FACR | November 19, 2021

A presentation at ACR Convergence 2021 discussed the 2020 ACR Guideline for the Management of Gout, the latest information on the risk of cardiovascular death associated with febuxostat and the use of pegloticase for patients with gout.

Colchicine: An Ancient Drug with Modern Uses

Ibrahem Salloum, MD, & Deepan S. Dalal, MD, MPH | August 11, 2021

Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550…

Case Report: Does a Young Woman with Gitelman Syndrome Have Gout?

Rebecca Lindsey Weiner, DO, & Ann K. Rosenthal, MD, FACP | June 14, 2021

Gout is the most common type of inflammatory arthritis in adults, and it typically occurs in men over the age of 50. When gout presents in younger patients or in women, this should warrant consideration of secondary causes. We describe an unusual genetic cause of tophaceous gout in a young, premenopausal woman. Case Report In…

Pegloticase Safe & Effective for Patients with Gout on Dialysis

Michele B. Kaufman, PharmD, BCGP | May 19, 2021

Pegloticase is safe and effective to treat patients with refractory gout who are undergoing dialysis, according to recently presented research.

Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial

Puja Khanna, Dinesh Khanna, Gary Cutter, Jeffrey Foster, Joshua Melnick, Sara Jaafar, Stephanie Biggers, AKM Rahman, Hui-Chen Kuo, Michelle Feese and Kenneth Saag | December 10, 2020

Short-term concomitant use of MMF with pegloticase was generally well tolerated in this proof-of-concept study. It was associated with a statistically significant and clinically meaningful impact on the proportion of subjects achieving and maintaining a sUA ≤6 mg/dL at 24 weeks. See the abstract with bonus video discussing the validation of proposed remission and completion criteria for the treatment of gout.